Could third time be the charm for Advair copycats? Novartis’ Sandoz aims to find out
admin 16th June 2017 Uncategorised 0The FDA has already struck down two generics of GlaxoSmithKline respiratory blockbuster Advair. But Novartis’ Sandoz is hoping its version can be the one to turn the tide.
More: Could third time be the charm for Advair copycats? Novartis’ Sandoz aims to find out
Source: fierce